Headlines:
Tag: Treatment
TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease a

TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease a

April 21, 2019 Economie

NEW YORK and LONDON, April 18, 2019 /PRNewswire/ -- TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a ...

Lees verder
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

February 11, 2019 Economie

Market Development Veteran Lisa Rogan Joins Nuvaira's Executive Team MINNEAPOLIS, Feb 11, 2019 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic medical devices to ...

Lees verder
Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

September 21, 2018 Economie

TOKYO, September 21, 2018 /PRNewswire/ -- If approved, mogamulizumab would be the first biologic agent targeting CCR4 to be available for patients in Europe.   Kyowa Hakko ...

Lees verder
Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

September 16, 2018 Economie

LISLE, Illinois, Sept. 14, 2018 /PRNewswire/ -- Endotronix, Inc. , a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the ...

Lees verder
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

August 8, 2018 Economie

TOKYO, August 8, 2018 /PRNewswire/ -- - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in ...

Lees verder
AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

July 29, 2018 Economie

CONFERENCE ALSO RELEASES FIRST-EVER DEMENTIA DATA IN LGB SENIORS, AND WOMEN'S DEMENTIA RISK RELATED TO REPRODUCTIVE HISTORY CHICAGO, July 25, 2018 /PRNewswire/ -- The first ...

Lees verder
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

May 18, 2018 Economie

NOVATO, California, TOKYO and LONDON, May 17, 2018 /PRNewswire/ -- Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients ...

Lees verder
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

April 30, 2018 Economie

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension ...

Lees verder
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hy

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hy

February 24, 2018 Economie

TOKYO, LONDON and NOVATO, California, February 23, 2018 /PRNewswire/ -- Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease Crysvita ...

Lees verder
GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

December 30, 2017 Economie

LONDON, December 29, 2017 /PRNewswire/ -- GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...

Lees verder
Nieuwe berichten
BizPress.nl